About
Experts
Webinars & Conferences
Webinars
Conference recordings
External Webinars
Antimicrobial Viewpoints
Resources
Library
Antimicrobial Encyclopaedia
Conference calendar
JOIN US
Log in
Lost your password?
Create your account
My account
Logout
You are here
:
Home
-
Phase 4
Advanced search
Search our library
Use the filters below to narrow your search:
Content format
Article
Definition
Encyclopaedia
External resource
Video
Resource type
Antimicrobial Viewpoint
Conference
Database
Funding Mechanism
Guideline
Organization
Presentation
Project
Protocol/SOP
Publication
Scientific Journal
Tool
Video
Webinar
Drug development
CMC
Discovery
Exploratory
Hit-to-lead
Lead-to-candidate
Phase 1
Phase 2
Phase 3
Phase 4
PK/PD
Preclinical development
Regulatory
Screening
Toxicology
Indication
ABSSI
Bloodstream infection
Gonorrhoea
HAP/VAP
IAI
Pneumonia
SSTI
STI
Tuberculosis
UTI
Microbe / Microbial properties
Acinetobacter baumannii
Enterobacteriaceae
Enterococcus faecium
Escherichia coli
ESKAPE
Gram negative
Gram positive
Klebsiella pneumoniae
MDR
PDR
Pseudomonas aeruginosa
Staphylococcus aureus
WHO priority pathogens
XDR
Antibiotics class
Aminoglycosides
Carbapenems
Cephalosporins
Diarylquinolines
Glycopeptides
Lincomycins
Macrolides
Penicillins
Quinolones
Sulfonamides
Tetracyclines
Other tags
Access
Diagnostics
Stewardship
Search
Antimicrobial Resistance Solutions
Bootcamp: Post-Approval Economics for New Antibiotics (ASM/ESCMID 2019)
European Committee on Antimicrobial Susceptibility Testing – EUCAST
Clinical & Laboratory Standards Institute: CLSI Guidelines
The antibiotics marketplace collapse: It’s just math, and it’s a solvable equation’
Developing antibiotics for children – medical need and regulatory challenges
Putting children first in the fight against antibiotic resistance
Adaptive trial
Phase 1, 2, 3, 4 trials
Clinical Development
Minimum inhibitory concentration (MIC)
Investigational new drug (IND)
Breakpoint concentration, clinical
Pharmacokinetics-pharmacodynamics (PK/PD)
Superiority trial
Plasma concentration
Antiseptic
Therapeutic window
Standard of care (SOC)
Sepsis
Randomized clinical trial (RCT)
Pro-drug
Pharmacovigilance
Drug product, medicinal product
Cmax
Antimicrobial susceptibility testing (AST), resistance testing
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Marketing authorization application (MAA)
Limited population pathway for antimicrobial and antifungal drugs (LPAD)
Non-inferiority trial
Active pharmaceutical ingredient (API)
We use cookies to improve your experience with our website. By continuing to browse our website, you are agreeing to our use of cookies. However, you can change your cookie settings at any time in your browser.
Read our
cookie policy